NCT01234337 / 2010-018501-10: Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer |
|
|
| Completed | 3 | 537 | Canada, Japan, US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006), Placebo, Capecitabine | Bayer, Onyx Therapeutics, Inc. | Breast Cancer | 05/14 | 10/17 | | |